Exploring minimally invasive approach to define stages of type 1 diabetes remotely |
|
Author: | Kontola, Helena1; Alanko, Inka1; Koskenniemi, Jaakko J1,2; |
Organizations: |
1Department of Pediatrics, Turku University Hospital, Turku, Finland 2Research Center for Integrative Physiology and Pharmacology, and Center for Population Health Research, Institute of Biomedicine, University of Turku, Turku, Finland 3Department of Biostatistics, University of Turku, Turku, Finland
4Pediatric Research Center, New Children's Hospital, Helsinki University Hospital, Helsinki, Finland
5Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland 6Center for Child Health Research, Tampere University Hospital, Tampere, Finland 7Department of Children and Adolescents, Oulu University Hospital, Oulu, Finland 8PEDEGO Research Unit, Department of Pediatrics, Medical Research Center, University of Oulu, Oulu, Finland |
Format: | article |
Version: | accepted version |
Access: | open |
Online Access: | PDF Full Text (PDF, 0.7 MB) |
Persistent link: | http://urn.fi/urn:nbn:fi-fe2023031431492 |
Language: | English |
Published: |
Mary Ann Liebert,
2022
|
Publish Date: | 2023-03-14 |
Description: |
AbstractObjectives: New methods are pivotal in accurately predicting, monitoring, and diagnosing the clinical manifestation of type 1 diabetes (T1D) in high-risk children. Continuous glucose monitoring (CGM) is a valuable tool for patients with T1D, but there is still a knowledge gap regarding its utility in the prediction of diabetes. The current study explored whether 10-day CGM or CGM during an oral glucose tolerance test (OGTT) performed in the laboratory or at home (home-OGTT) could be accurate in detecting stages of T1D. Research Design and Method: Forty-six subjects 4–25 years of age carrying genetic risk for T1D were recruited and classified into the following groups: islet autoantibody (IAb) negative, one IAb, and stages 1–3 of T1D, based on the laboratory OGTT and IAb results at baseline. A 10-day CGM was initiated before the OGTT. Results: In this study, we showed that CGM was sensitive in detecting asymptomatic individuals at stage 3, and dysglycemic individuals in stage 2 of T1D both during OGTT and the 10-day period. CGM also showed significant differences in several variables during the 10-day sensoring among individuals at different stages of T1D. Furthermore, CGM showed different OGTT profiles and detected significantly more abnormal OGTT results when compared with plasma glucose. Conclusions: CGM together with home-OGTT could detect stages of T1D and offer an alternative method to confirm normoglycemia in high-risk individuals. see all
|
Series: |
Diabetes technology & therapeutics |
ISSN: | 1520-9156 |
ISSN-E: | 1557-8593 |
ISSN-L: | 1520-9156 |
Volume: | 24 |
Issue: | 9 |
Pages: | 655 - 665 |
DOI: | 10.1089/dia.2021.0554 |
OADOI: | https://oadoi.org/10.1089/dia.2021.0554 |
Type of Publication: |
A1 Journal article – refereed |
Field of Science: |
3121 General medicine, internal medicine and other clinical medicine |
Subjects: | |
Funding: |
We thank the following funding organizations: JDRF International, Sigrid Juselius Foundation, Finland, Pediatric Research Foundation, Finland and Turku University Hospital Special Governmental Funding. |
Copyright information: |
© 2022, Mary Ann Liebert, Inc., publishers. This is the accepted version of the following article: Helena Kontola, Inka Alanko, Jaakko J. Koskenniemi, Eliisa Löyttyniemi, Saori Itoshima, Mikael Knip, Riitta Veijola, Jorma Toppari, and Jukka Kero. Exploring Minimally Invasive Approach to Define Stages of Type 1 Diabetes Remotely. Diabetes Technology & Therapeutics.Sep 2022.655-665, which has now been formally published in final form at Diabetes Technology & Therapeutics at http://doi.org/10.1089/dia.2021.0554. This original submission version of the article may be used for non-commercial purposes in accordance with the Mary Ann Liebert, Inc., publishers’ self-archiving terms and conditions. |